0
Signin
countryflagUS

18889881171

AAPL 165.84 0.5091% MSFT 400.96 0.461% GOOG 157.95 1.4321% GOOGL 156.28 1.4212% AMZN 177.23 1.4889% NVDA 795.18 4.3543% META 481.73 0.1372% TSLA 142.05 -3.4002% TSM 129.75 1.6053% LLY 731.33 0.6912% V 272.33 0.9452% AVGO 1224.46 1.6394% JPM 189.41 1.9429% UNH 491.23 -1.9755% NVO 125.26 2.0781% WMT 60.14 1.0247% LVMUY 168.89 0.4222% XOM 120.57 0.5756% LVMHF 851.89 0.4528% MA 456.75 0.2986%

PDS Biotechnology Corp

Healthcare US PDSB

2.99USD
0.34(13.04%)

Last update at 2024-04-22T20:00:00Z

Day Range

2.643.00
LowHigh

52 Week Range

3.8013.65
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -42.05376M -21.43496M -14.84738M -7.38012M -43.64994M
Minority interest - - - - -
Net income -40.85486M -16.91848M -14.84738M -6.99861M -40.86801M
Selling general administrative 12.24M 10.18M 6.96M 10.98M 14.29M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.00009M 0.00536M 0.02M 0.10M 0.17M
Ebit -41.67242M -21.43931M -14.90239M -21.03462M -29.48790M
Ebitda -40.73724M -21.43395M -14.83177M -16.72786M -29.31355M
Depreciation and amortization 0.94M 0.00536M 0.07M 4.31M 0.17M
Non operating income net other - - 0.06M - -
Operating income -41.67242M -21.43931M -14.90239M -21.03462M -43.09657M
Other operating expenses 41.67M 21.44M 14.90M 17.08M 30.36M
Interest expense 1.32M 0.00435M 0.00000M 0.03M 1.43M
Tax provision -1.19891M -4.51649M 0.00000M -0.38151M -2.78194M
Interest income 0.94M 0.00435M 0.06M 0.35M 0.87M
Net interest income -0.38134M 0.00435M 0.06M 0.32M -0.55338M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.19891M -4.51649M -0.05501M -0.38151M -2.78194M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 41.67M 21.44M 14.90M 17.08M 30.36M
Cost of revenue - - - - -
Total other income expense net -0.38134M 0.00435M 0.06M 13.65M -12.73679M
Discontinued operations - - - - -
Net income from continuing ops -40.85486M -16.91848M -14.84738M -6.99861M -40.86801M
Net income applicable to common shares -40.85486M -16.91848M -14.84738M -6.99861M -3.83648M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 77.01M 67.20M 30.89M 14.49M 36.22M
Intangible assets - - - - 0.04M
Earning assets - - - - -
Other current assets 2.66M 1.60M 1.50M 2.31M 1.01M
Total liab 33.01M 3.99M 3.76M 2.79M 6.38M
Total stockholder equity 44.00M 63.21M 27.13M 11.70M 29.84M
Deferred long term liab - - - - -
Other current liab 8.31M 2.19M 1.74M 1.60M 5.98M
Common stock 0.00996M 0.00939M 0.00735M 0.00174M 0.01M
Capital stock 0.00996M 0.00939M 0.00735M 0.00174M 0.01M
Retained earnings -101.55842M -60.70356M -43.78509M -28.93771M -192.81636M
Other liab - - - - 0.29M
Good will - - - - -
Other assets - - 0.55M - 0.01M
Cash 73.82M 65.24M 28.84M 12.16M 34.65M
Cash and equivalents - - - - -
Total current liabilities 9.82M 3.76M 3.27M 2.79M 6.38M
Current deferred revenue - - - - -
Net debt -50.34726M -64.75227M -28.22931M -12.16174M -34.64555M
Short term debt 0.29M 0.26M 0.12M - -
Short long term debt - - - - -
Short long term debt total 23.47M 0.49M 0.61M - -
Other stockholder equity 145.55M 123.90M 70.91M 40.63M 223.10M
Property plant equipment 0.53M 0.36M 0.55M 0.02M 0.03M
Total current assets 76.48M 66.84M 30.34M 14.47M 35.65M
Long term investments - - - - -
Net tangible assets 44.00M 63.21M 27.13M 11.70M -2.06621M
Short term investments - - - - -
Net receivables - - - - -
Long term debt 23.02M - - - 0.03M
Inventory - - - - -
Accounts payable 1.22M 1.31M 1.42M 1.20M 0.40M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -0.09437M -0.45166M
Additional paid in capital - - - - -
Common stock total equity 0.00996M - 0.00735M 0.00174M 0.01M
Preferred stock total equity - - - - -
Retained earnings total equity -101.55842M - -43.78509M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.37M - 0.55M 0.02M 0.14M
Deferred long term asset charges - - - - -
Non current assets total 0.53M 0.36M 0.55M 0.02M 0.57M
Capital lease obligations 0.45M 0.49M 0.61M - -
Long term debt total 23.02M - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - - 0.00000M 29.38M 0.00000M
Change to liabilities 6.04M -0.10582M 0.22M -1.97767M 0.79M
Total cashflows from investing activities - - - 29.38M 29.38M
Net borrowings 24.55M 25.00M 25.00M 25.00M -0.01556M
Total cash from financing activities 34.29M 48.89M 29.83M 0.75M -20.26881M
Change to operating activities 4.57M 0.18M 0.85M -2.62688M 0.36M
Net income -40.85486M -16.91848M -14.84738M -6.99861M -40.86801M
Change in cash 8.58M 36.40M 16.68M 12.06M -53.42210M
Begin period cash flow 65.24M 28.84M 12.16M 0.10M 88.07M
End period cash flow 73.82M 65.24M 28.84M 12.16M 34.65M
Total cash from operating activities -25.70971M -12.48607M -13.14913M -18.07347M -33.15329M
Issuance of capital stock 9.86M 48.54M 29.76M 0.75M 0.00000M
Depreciation 0.00009M 0.00536M 0.02M 0.10M 0.17M
Other cashflows from investing activities - - - 29.38M -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 10.01M - 29.83M 0.75M 0.72M
Other cashflows from financing activities 24.88M 0.34M 0.07M 29.38M 0.72M
Change to netincome 5.20M 4.35M 0.61M -6.56873M 1.05M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating 3.73M - 0.87M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes 8.58M - 16.68M - -
Change in working capital 4.47M 0.08M 1.07M -4.60455M -3.42850M
Stock based compensation 5.20M 4.11M 0.45M 3.18M 7.61M
Other non cash items 5.47M 0.24M 0.16M -9.36335M 0.53M
Free cash flow -25.70971M -12.48607M -13.14913M -18.07347M -33.15329M

Fundamentals

  • Previous Close 2.65
  • Market Cap165.80M
  • Volume683766
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-51.40513M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.71

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
PDSB
PDS Biotechnology Corp		 0.34 13.04% 2.99 - - - 6.17 -2.4789
NVO
Novo Nordisk A/S		 2.55 2.08% 125.26 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 3.76 3.07% 126.26 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.64 1.43% 399.92 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 2.35 2.71% 89.17 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

PDS Biotechnology Corp

25B Vreeland Road, Florham Park, NJ, United States, 07932

Key Executives

Name Title Year Born
Dr. Frank K. Bedu-Addo Ph.D. Pres, CEO & Director 1965
Mr. Matthew C. Hill CPA CFO, Principal Financial & Accounting Officer 1969
Dr. Gregory L. Conn Ph.D. Chief Scientific Officer 1955
Ms. Lauren V. Wood M.D. Chief Medical Officer 1960
Dr. Joe J. Dervan VP of R&D NA
Ms. Deanne Randolph VP of Commercial Devel. & Head of Investor Relations NA
Mr. Spencer Brown J.D. Sr. VP & Gen. Counsel NA
Ms. Nathalie Riebel Sr. VP of Clinical Operations NA
Mr. Sanjay Zaveri Sr. VP of Bus. Devel. NA
Ms. Janetta Trochimiuk Controller 1963

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).